Plexitome™, an innovative device designed for anterior stromal puncture (ASP), is now being introduced through a strategic collaboration between Plexitome Medical and VEO Ophthalmics, a recognized leader in advanced ophthalmic technologies. This breakthrough tool is engineered to deliver unmatched accuracy and consistency, positioning it as a transformative solution for treating Recurrent Corneal Erosion (RCE) and various epithelial basement membrane dystrophies (EBMD).
Traditional ASP techniques often depend on manual precision, which can lead to unpredictable results. Plexitome™ sets a new standard by incorporating a 6.2 mm diameter disc array outfitted with approximately 675 meticulously crafted micro-spikes. This configuration ensures uniform puncture depth through Bowman’s layer of the cornea while avoiding optically significant anterior stromal scarring. With the potential to create up to 3,375 epithelial attachment points over five carefully placed imprints, the device promotes better corneal healing and significantly reduces the likelihood of recurrence over time.
“Plexitome™ represents a significant breakthrough in the treatment of corneal conditions, especially those that affect the optical axis,” stated Dr. Edward Chaum, Plexitome Medical’s founder and chief medical officer. This device was developed to enhance patient outcomes while eliminating the variability and limitations associated with traditional manual ASP. By collaborating with VEO Ophthalmics, we can take advantage of their experience launching cutting-edge ophthalmic solutions.”
Ron Gilliland, Chief Executive Officer of VEO Ophthalmics, added, “Plexitome Medical has created a truly novel approach to addressing RCE and extensive corneal abrasions. PlexitomeTM, in our opinion, will transform the way corneal experts approach and carry out anterior stromal puncture. We look forward to working alongside Plexitome Medical to bring this technology to clinicians and their patients.”
Early clinical use has shown that Plexitome™ can penetrate Bowman’s layer effectively through both debrided and intact epithelium, producing stable epithelial attachment even in situations where manual ASP methods have been less effective. It also has the potential to accelerate healing times for large corneal abrasions and reduce the risk of future erosions. VEO Ophthalmics will oversee the commercial introduction of Plexitome™, providing access, training, and support to corneal specialists and surgical teams across the United States and international markets.
